SPOTLIGHT -
Contemporary Oncology®: Biomarkers, Pathways, and Targeted Therapies® - May 2022
Volume: 1
Issue: 1
Contemporary Oncology®: Biomarkers, Pathways, and Targeted Therapies® - March 2018
August 2015
Volume: 7
Issue: 3
April 2015
Issue: 2
February 2015
November 2014
Volume: 6
Issue: 4
August 2014
April 2014
February 2014
Winter 2013
Volume: 5
Fall 2013
Summer 2013
Spring 2013
Summer 2012
Volume: 4
Spring 2012
Fall 2011
Volume: 3
Summer 2011
Spring 2011
Winter 2010
Volume: 2
Fall 2010
Summer 2010
Spring 2010
Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma
TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy
Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC
